Enlivex Therapeutics (NASDAQ:ENLV – Get Free Report) and Korro Bio (NASDAQ:KRRO – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, dividends, analyst recommendations and risk.
Valuation & Earnings
This table compares Enlivex Therapeutics and Korro Bio”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Enlivex Therapeutics | N/A | N/A | $1.24 billion | ($8.25) | -0.57 |
| Korro Bio | $6.39 million | 27.64 | -$117.26 million | ($11.67) | -1.05 |
Risk & Volatility
Enlivex Therapeutics has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500. Comparatively, Korro Bio has a beta of 3, suggesting that its share price is 200% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings for Enlivex Therapeutics and Korro Bio, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Enlivex Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
| Korro Bio | 1 | 2 | 6 | 3 | 2.92 |
Enlivex Therapeutics currently has a consensus target price of $247.50, indicating a potential upside of 5,188.46%. Korro Bio has a consensus target price of $16.71, indicating a potential upside of 36.44%. Given Enlivex Therapeutics’ higher probable upside, analysts plainly believe Enlivex Therapeutics is more favorable than Korro Bio.
Profitability
This table compares Enlivex Therapeutics and Korro Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Enlivex Therapeutics | N/A | 248.08% | 206.39% |
| Korro Bio | -1,834.48% | -117.86% | -71.04% |
Institutional and Insider Ownership
1.0% of Enlivex Therapeutics shares are owned by institutional investors. Comparatively, 13.2% of Korro Bio shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by insiders. Comparatively, 4.8% of Korro Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Enlivex Therapeutics beats Korro Bio on 8 of the 14 factors compared between the two stocks.
About Enlivex Therapeutics
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
About Korro Bio
Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Enlivex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enlivex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
